185 related articles for article (PubMed ID: 10931589)
1. MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer.
Romijn MG; Stoker J; van Eijck CH; van Muiswinkel JM; Torres CG; Laméris JS
J Magn Reson Imaging; 2000 Aug; 12(2):261-8. PubMed ID: 10931589
[TBL] [Abstract][Full Text] [Related]
2. MRI with mangafodipir trisodium in the detection of pancreatic tumours: comparison with helical CT.
Rieber A; Tomczak R; Nüssle K; Klaus H; Brambs HJ
Br J Radiol; 2000 Nov; 73(875):1165-9. PubMed ID: 11144793
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT.
Schima W; Függer R; Schober E; Oettl C; Wamser P; Grabenwöger F; Ryan JM; Novacek G
AJR Am J Roentgenol; 2002 Sep; 179(3):717-24. PubMed ID: 12185052
[TBL] [Abstract][Full Text] [Related]
4. Secretin-stimulated multi-detector CT versus mangafodipir trisodium-enhanced MR imaging plus MRCP in characterization of non-metastatic solid pancreatic lesions.
Boraschi P; Donati F; Gigoni R; Salemi S; Faggioni L; Del Chiaro M; Boggi U; Bartolozzi C; Falaschi F
Dig Liver Dis; 2009 Nov; 41(11):829-37. PubMed ID: 19303825
[TBL] [Abstract][Full Text] [Related]
5. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
6. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET.
Sahani DV; Kalva SP; Fischman AJ; Kadavigere R; Blake M; Hahn PF; Saini S
AJR Am J Roentgenol; 2005 Jul; 185(1):239-46. PubMed ID: 15972430
[TBL] [Abstract][Full Text] [Related]
7. Identification and staging of pancreatic tumours using computed tomography, endoscopic ultrasound and mangafodipir trisodium-enhanced magnetic resonance imaging.
Ramsay D; Marshall M; Song S; Zimmerman M; Edmunds S; Yusoff I; Cullingford G; Fletcher D; Mendelson R
Australas Radiol; 2004 Jun; 48(2):154-61. PubMed ID: 15230749
[TBL] [Abstract][Full Text] [Related]
8. Influence of the hepatobiliary contrast agent mangafodipir trisodium (MN-DPDP) on the imaging properties of abdominal organs.
Jung G; Heindel W; Krahe T; Kugel H; Walter C; Fischbach R; Klaus H; Lackner K
Magn Reson Imaging; 1998 Oct; 16(8):925-31. PubMed ID: 9814775
[TBL] [Abstract][Full Text] [Related]
9. Characterization of focal liver lesions: use of mangafodipir trisodium (MnDPDP)-enhanced MR images.
Karabacakoğlu A; Adigüzel Y; Karaköse S; Kayaçetin E; Haykir R
Turk J Gastroenterol; 2006 Sep; 17(3):164-71. PubMed ID: 16941248
[TBL] [Abstract][Full Text] [Related]
10. Mangafodipir trisodium-enhanced magnetic resonance imaging for evaluation of pancreatic mass and mass-like lesions.
Eser G; Karabacakoglu A; Karakose S; Eser C; Kayacetin E
World J Gastroenterol; 2006 Mar; 12(10):1603-6. PubMed ID: 16570354
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance with manganese-DPDP (mangafodipir) of focal solid pancreatic lesions.
Zanello A; Nicoletti R; Brambilla P; Boccuni R; Di Carlo V; Staudacher C; Del Maschio A
Radiol Med; 2004 Sep; 108(3):194-207. PubMed ID: 15343134
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium.
Mayo-Smith WW; Schima W; Saini S; Slater GJ; McFarland EG
AJR Am J Roentgenol; 1998 Mar; 170(3):649-52. PubMed ID: 9490946
[TBL] [Abstract][Full Text] [Related]
13. Comparison of mangafodipir trisodium- and ferucarbotran-enhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients.
Kim HJ; Kim KW; Byun JH; Won HJ; Shin YM; Kim PN; Lee MS; Lee MG
AJR Am J Roentgenol; 2006 Apr; 186(4):1059-66. PubMed ID: 16554579
[TBL] [Abstract][Full Text] [Related]
14. Small (Kim KW; Kim AY; Kim TK; Park SH; Kim HJ; Lee YK; Park MS; Ha HK; Kim PN; Kim JC; Lee MG
AJR Am J Roentgenol; 2004 May; 182(5):1233-40. PubMed ID: 15100125
[TBL] [Abstract][Full Text] [Related]
15. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging.
Scharitzer M; Schima W; Schober E; Reimer P; Helmberger TK; Holzknecht N; Stadler A; Ba-Ssalamah A; Weber M; Wrba F
J Comput Assist Tomogr; 2005; 29(2):181-90. PubMed ID: 15772534
[TBL] [Abstract][Full Text] [Related]
16. Defining intrahepatic biliary anatomy in living liver transplant donor candidates at mangafodipir trisodium-enhanced MR cholangiography versus conventional T2-weighted MR cholangiography.
Lee VS; Krinsky GA; Nazzaro CA; Chang JS; Babb JS; Lin JC; Morgan GR; Teperman LW
Radiology; 2004 Dec; 233(3):659-66. PubMed ID: 15516606
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of focal pancreatic masses: comparison of mangafodipir-enhanced MR imaging and contrast-enhanced helical CT.
Schima W; Függer R
Eur Radiol; 2002 Dec; 12(12):2998-3008. PubMed ID: 12439582
[TBL] [Abstract][Full Text] [Related]
18. MRI of the pancreas: tumours and tumour-simulating processes.
Schima W
Cancer Imaging; 2006 Dec; 6(1):199-203. PubMed ID: 17208676
[TBL] [Abstract][Full Text] [Related]
19. [Mangafodipir trisodium-enhanced magnetic resonance cholangiography for detection of bile leaks].
Assaban M; Aubé C; Lebigot J; Ridereau-Zins C; Hamy A; Caron C
J Radiol; 2006 Jan; 87(1):41-7. PubMed ID: 16415779
[TBL] [Abstract][Full Text] [Related]
20. Mangafodipir trisodium-enhanced MR imaging of pancreatic disease.
Boraschi P; Donati F; Gigoni R; Caramella D; Boggi U; Falaschi F; Bartolozzi C
Eur Radiol; 2006 May; 16(5):988-97. PubMed ID: 16421713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
